Current Report Filing (8-k)
February 04 2021 - 02:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 1, 2021
Titan
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341
|
94-3171940
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080
(Address of principal
executive offices and zip code)
650-244-4990
(Registrant's telephone
number including area code)
(Registrant's former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
TTNP
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On February 1, 2021, Titan Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing that studies of its kappa opioid agonist peptide, JT-09, has
demonstrated high potency and specificity for the human kappa-opioid receptor. JT-09 is being developed for use
in combination with the Company’s ProNeura® long-term, continuous drug delivery technology for the treatment of moderate-to-severe
chronic pruritus (itch). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
The following exhibit is filed herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: February 4, 2021
|
TITAN PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Kate Beebe Devarney, Ph.D.
|
|
Name:
|
Kate Beebe Devarney, Ph.D.
|
|
Title:
|
President and Chief Operating Officer
|
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Mar 2023 to Mar 2024